These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 18272495)

  • 1. Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn.
    Mezo AR; McDonnell KA; Hehir CA; Low SC; Palombella VJ; Stattel JM; Kamphaus GD; Fraley C; Zhang Y; Dumont JA; Bitonti AJ
    Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2337-42. PubMed ID: 18272495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
    Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A
    MAbs; 2015; 7(2):331-43. PubMed ID: 25658443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and structure-activity relationships of small molecules that block the human immunoglobulin G-human neonatal Fc receptor (hIgG-hFcRn) protein-protein interaction.
    Wang Z; Fraley C; Mezo AR
    Bioorg Med Chem Lett; 2013 Mar; 23(5):1253-6. PubMed ID: 23375228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
    Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
    J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.
    Smith B; Kiessling A; Lledo-Garcia R; Dixon KL; Christodoulou L; Catley MC; Atherfold P; D'Hooghe LE; Finney H; Greenslade K; Hailu H; Kevorkian L; Lightwood D; Meier C; Munro R; Qureshi O; Sarkar K; Shaw SP; Tewari R; Turner A; Tyson K; West S; Shaw S; Brennan FR
    MAbs; 2018 Oct; 10(7):1111-1130. PubMed ID: 30130439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
    Wang Y; Tian Z; Thirumalai D; Zhang X
    J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization and screening of IgG binding to the neonatal Fc receptor.
    Neuber T; Frese K; Jaehrling J; Jäger S; Daubert D; Felderer K; Linnemann M; Höhne A; Kaden S; Kölln J; Tiller T; Brocks B; Ostendorp R; Pabst S
    MAbs; 2014; 6(4):928-42. PubMed ID: 24802048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationships of a peptide inhibitor of the human FcRn:human IgG interaction.
    Mezo AR; McDonnell KA; Castro A; Fraley C
    Bioorg Med Chem; 2008 Jun; 16(12):6394-405. PubMed ID: 18501614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody.
    Maeda A; Iwayanagi Y; Haraya K; Tachibana T; Nakamura G; Nambu T; Esaki K; Hattori K; Igawa T
    MAbs; 2017 Jul; 9(5):844-853. PubMed ID: 28387635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.
    Yeung YA; Leabman MK; Marvin JS; Qiu J; Adams CW; Lien S; Starovasnik MA; Lowman HB
    J Immunol; 2009 Jun; 182(12):7663-71. PubMed ID: 19494290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Dual Targeting of FcRn and FcγRs
    Monnet C; Jacque E; de Romeuf C; Fontayne A; Abache T; Fournier N; Dupont G; Derache D; Engrand A; Bauduin A; Terrier A; Seifert A; Beghin C; Longue A; Masiello N; Danino L; Nogre M; Raia A; Dhainaut F; Fauconnier L; Togbe D; Reitinger C; Nimmerjahn F; Stevens W; Chtourou S; Mondon P
    Front Immunol; 2021; 12():728322. PubMed ID: 34512662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. X-ray crystal structures of monomeric and dimeric peptide inhibitors in complex with the human neonatal Fc receptor, FcRn.
    Mezo AR; Sridhar V; Badger J; Sakorafas P; Nienaber V
    J Biol Chem; 2010 Sep; 285(36):27694-701. PubMed ID: 20592032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the neonatal fc receptor for antigen delivery using engineered fc fragments.
    Mi W; Wanjie S; Lo ST; Gan Z; Pickl-Herk B; Ober RJ; Ward ES
    J Immunol; 2008 Dec; 181(11):7550-61. PubMed ID: 19017944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies.
    Schlothauer T; Rueger P; Stracke JO; Hertenberger H; Fingas F; Kling L; Emrich T; Drabner G; Seeber S; Auer J; Koch S; Papadimitriou A
    MAbs; 2013; 5(4):576-86. PubMed ID: 23765230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life.
    Andersen JT; Foss S; Kenanova VE; Olafsen T; Leikfoss IS; Roopenian DC; Wu AM; Sandlie I
    J Biol Chem; 2012 Jun; 287(27):22927-37. PubMed ID: 22570488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A strategy for bacterial production of a soluble functional human neonatal Fc receptor.
    Andersen JT; Justesen S; Berntzen G; Michaelsen TE; Lauvrak V; Fleckenstein B; Buus S; Sandlie I
    J Immunol Methods; 2008 Feb; 331(1-2):39-49. PubMed ID: 18155020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.
    Ulrichts P; Guglietta A; Dreier T; van Bragt T; Hanssens V; Hofman E; Vankerckhoven B; Verheesen P; Ongenae N; Lykhopiy V; Enriquez FJ; Cho J; Ober RJ; Ward ES; de Haard H; Leupin N
    J Clin Invest; 2018 Oct; 128(10):4372-4386. PubMed ID: 30040076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.
    Vaccaro C; Zhou J; Ober RJ; Ward ES
    Nat Biotechnol; 2005 Oct; 23(10):1283-8. PubMed ID: 16186811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.
    Petkova SB; Akilesh S; Sproule TJ; Christianson GJ; Al Khabbaz H; Brown AC; Presta LG; Meng YG; Roopenian DC
    Int Immunol; 2006 Dec; 18(12):1759-69. PubMed ID: 17077181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deciphering the Interaction between Neonatal Fc Receptor and Antibodies Using a Homogeneous Bioluminescent Immunoassay.
    Nath N; Godat B; Flemming R; Urh M
    J Immunol; 2021 Aug; 207(4):1211-1221. PubMed ID: 34312257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.